While MYC-amplified tumors may be more sensitive to translation inhibition, RAS-driven cancers such as PDAC and non-small cell lung cancer also depend on MYC52,79, making them promising indications for such a therapeutic approach. Here, MYC is linked to non-small cell lung carcinoma.